Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark

Søg

Menu

Close

Log indLog udLægemidlerTerapiområderPfizerConnectPfizerConnectArrangementerMaterialerEfteruddannelse
AboutAlopecia AreataLITFULO Mechanism of ActionSALT EvaluationEfficacyALLEGRO-2b/3 Study OverviewScalp Hair ResponsePatient-reported OutcomesEyebrow & Eyelash ResponseBefore & After ImagesSafetyALLEGRO-2b/3 Adverse ReactionsAdditional Safety ConsiderationsGetting StartedDosingScreening & MonitoringSetting Patient ExpectationsResourcesMaterialsVideos
Dosing LITFULO 50 mg capsules.
One dose strength. One pill. Once a day.[1] 
Scroll left to view table
How to take
  • With or without food
  • Capsules should be swallowed whole; not crushed, split, or chewed
If a dose is missed
  • Patients should take it as soon as possible
  • If less than 8 hours before the next dose, resume dosing at the regular scheduled time
Treatment interruption or discontinuation
  • Interrupt LITFULO if a serious or opportunistic infection develops, and resume treatment once the infection is controlled
  • Interruption or discontinuation of treatment may be needed to manage haematologic abnormalities
 
  • The risk of significant loss of regrown scalp hair after a temporary treatment interruption for less than 6 weeks is low

Table made by Pfizer based on data in ref. 1

Update immunisations according to current local guidelines before initiating LITFULO, including prophylactic herpes zoster vaccinations.[1]  
Avoid using live attenuated vaccines during or shortly prior to treatment with LITFULO.[1] Drug Interactions
Scroll left to view table
 Clinical ImpactIntervention
Effects of LITFULO on other drugs
CYP3A and CYP1A2LITFULO is a CYP3A and CYP1A2 inhibitor that may increase the risk of adverse reactions of these substratesCaution should be exercised with concomitant use of LITFULO with other CYP3A and CYPIA2 substrates where moderate concentration changes may lead to serious adverse reactions. Dose adjustment recommendations for the other drugs should be considered
OCT1 substratesThe coadministration of a single 400 mg dose of ritlecitinib increased the AUCinf of sumatriptan (an organic cation transporter [OCT]1 substrate) by approximately 1.3- to 1.5-fold relative to the sumatriptan dose given alone. The increase in sumatriptan exposure is not considered clinically relevantCaution should be exercised with concomitant use of ritlecitinib with OCT1 substrates where small concentration changes may lead to serious adverse reactions
Effects of other drugs on LITFULO
Moderate-to-strong inducers or inhibitors of CYP3AConcomitant use of strong CYP3A inducers or inhibitors may affect the AUC of LITFULOThe effects of these other drugs on LITFULO were not considered clinically significant, and no dose adjustment is required

Table made by Pfizer based on data in ref. 1

 Learn how to get patients started on LITFULO Screening & monitoring LoadingAUC=area under curve; CYP1A2=Cytochrome P450 Family 1 Subfamily A Member 2; CYP3A=Cytochrome P450 Family 3 Subfamily A.ReferencesReference:1. LITFULO (ritlecitinib) SmPC. Getting Started Explore safety data SafetyLoading
 Indication Litfulo® (ritlecitinib):
 Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.[Litfulo SmPC] 
 Litfulo pligttekst

Bivirkninger skal indberettes. Hvis du vil rapportere en bivirkning, kan du kontakte Pfizer på e-mail: [email protected]

 

PfizerPro kontoPfizerPro konto

Få adgang til information, materialer, efteruddannelse samt modtag kommunikation om Pfizers lægemidler og vacciner.

Log indRegisterMin profilLog ud

Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark.

Denne hjemmeside er udarbejdet til dig af Pfizer Danmark.

 

© Pfizer 2023. Alle rettigheder til denne hjemmeside forbeholdes Pfizer ApS.

12 August 2025 * PP-LGF-DNK-0008
Du forlader nu Pfizer
Du forlader nu et Pfizer-drevet website. Links til alle eksterne websites leveres som en ressource til vores besøgende. Pfizer påtager sig intet ansvar for indholdet af websites, der ikke ejes og drives af Pfizer.